Answers are grounded in this paper and cite their sources.
Purpose – High‐secure hospital patients often have complex presentations that are marked by co‐morbidity, violence, histories of poor concordance with oral medication, and treatment resistance. The ability to give a long‐acting medication with a low propensity for extra pyramidal side effects is of potential value to clinicians treating these patients. Risperidone Long‐acting Injection (RLAI) is the first long‐acting atypical antipsychotic medication and may be potentially useful in this population. This paper aims to investigate this issue.
No takes yet. Share an insight, caveat, or question.
Gibbon et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: